Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in pa... Read more
FREE Market Signals & Ideas!
You will never miss our latest news, trading ideas, podcasts, and market signals.
You have successfully joined our subscriber list.
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.